Manulife Connect Cambodian Customer to Award-Winning Multi-Cancer Screening in Singapore
Take a proactive step toward protecting your future
As part of Manulife's commitment to helping customers live better and achieve longevity, we are providing access to the Multi-Cancer Detection (MCD) Test, an innovative blood-based screening technology designed to detect 10 types of cancer from a single blood draw, through Guardant Health, a global leader in blood-based cancer testing with over a decade of experience¹. This exclusive partnership marks the first introduction of the Guardant Health MCD test* in Asia and empowers customers with earlier cancer detection capabilities.
Here’s how you can access the Multi-Cancer Detection (MCD)* test:
- Speak with a Manulife Insurance Advisor
- Purchase a suitable plan
- Eligible customers receive a complimentary Multi-Cancer Detection (MCD) test* worth up to USD 1,500.
Eligible customers can stand a chance to receive a complimentary MCD Test worth up to USD 1,500 through an exclusive offer from Manulife
Why This Matters for Cambodian Customers
In Cambodia, around 50 people are diagnosed with cancer every day, while approximately 38 lives are lost to the disease. One of the biggest challenges is that cancer is often detected at a later stage, when treatment becomes more costly and recovery outcomes can be less favorable.
That's why the Multi-Cancer Detection (MCD) Test can make a meaningful difference. Through a simple blood draw, it helps identify cancer signals earlier, empowering individuals to seek medical attention sooner, prepare financially, and take proactive steps toward better health outcomes and a healthier future.
Live Longer. Live Better. Live with Confidence.
What is Multi-Cancer Detection (MCD)* test by Guardant Health?
The Guardant Health MCD Test* is intended to detect 10 cancers – bladder, breast, colorectal, esophageal, stomach, liver, lung, ovarian, pancreatic and prostate cancer through a single blood draw.
The MCD Test* by Guardant Health is:
- Scientifically proven, with technology backed by over 1 million oncology blood samples tested
- Innovative - Guradant Health's MCD test has received US FDA breakthrough device designation's
For more information, please click here.
Sources: